铜-KRAS-COX2轴:胰腺癌的治疗脆弱性
Joyeeta Roy1, Rima Mouawad1, Armita Kyani1
1Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, North Campus Research Complex, 1600 Huron Parkway, Ann Arbor, Michigan 48109, United States.
Journal of medicinal chemistry
|March 26, 2025
概括
研究人员开发了新型烯酸胺来治疗胰腺管腺癌 (PDAC) 通过向铜. 优化的化合物52在临床前模型中显示了与赛莱科西布的有效性和协同作用.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 癌症生物学 癌症生物学
背景情况:
- 在胰腺管腺癌 (PDAC) 中,KRAS突变很普遍,导致瘤生长.
- PDAC瘤对铜的依赖程度很高,因此具有治疗脆弱性.
- 准铜平衡是PDAC治疗的一个有前途的策略.
研究的目的:
- 为了发现和优化用于PDAC治疗的新奇奇烯酸化物.
- 为了研究作用机制,包括铜介导的细胞死亡.
- 评估优化化合物的体内疗效和安全性.
主要方法:
- 结构-活性关系 (SAR) 研究是对金烯酸胺类同类物进行的.
- 化合物被评估为它们诱导亡和亡的能力.
- 在PDAC模型中进行了体外和体外研究.
- 评估了药理动力学和药理动力学特性.
主要成果:
- 新型烯酸胺被确定为强大的诱导铜介导细胞死亡的诱导剂.
- 优化化合物39和52表现出有利的类似药物的特性,包括水溶性和代谢稳定性.
- 化合物52在PDAC模型中显示出显著的口服生物可用性 (55%) 和体内疗效,没有明显的毒性.
- 化合物52在体外和体外环境中表现出与赛莱科克西布的协同作用.
结论:
- 奎诺基金胺有效地准PDAC中的铜恒温.
- 化合物52是对KRAS突变癌症的有前途的治疗候选物.
- 与塞莱科克西布的联合治疗可能会改善PDAC的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Chronic Pancreatitis II: Collaborative Care
51
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
51
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Canonical Wnt Signaling Pathway
8.6K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.6K
Non-Canonical Wnt Signaling Pathways
7.2K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.2K


